Distant recurrence in a patient with polyp-confined stage IA serous endometrial carcinoma treated with adjuvant chemotherapy: A case report and review of literature.
Adjuvant treatment
Metastasis
Polyp
Serous
Uterus
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
10
09
2019
revised:
15
10
2019
accepted:
20
10
2019
entrez:
1
1
2020
pubmed:
1
1
2020
medline:
1
1
2020
Statut:
epublish
Résumé
Uterine serous carcinoma is a rare, high-risk histological subtype of endometrial cancer, and use of adjuvant treatment in early stage IA disease is inconsistent, especially when the tumor is confined entirely within an endometrial polyp. We herein present a case of extrauterine recurrence in a 67-year-old female with polyp-confined, stage IA uterine serous endometrial cancer. She underwent comprehensive surgical staging with the pathology returning a 5 cm uterine serous carcinoma confined completely to a 7 cm polyp with negative margins, negative myometrial and lymphovascular space invasion, and twenty-nine negative para-aortic and pelvic lymph nodes. She went on to complete six cycles of adjuvant carboplatin and paclitaxel. She presented with a new pleural effusion approximately 20 months after receiving definitive treatment, and a diagnosis of recurrent, metastatic uterine serous carcinoma was confirmed through cytology. A review of the literature suggests practice patterns involving adjuvant treatment for polyp-confined stage IA uterine serous carcinoma are highly variable. Prospective studies clarifying the utility of adjuvant treatment for polyp-confined disease in comprehensively staged patients, especially pertaining to the impact this pathology has on recurrence risk, are needed for these patients.
Identifiants
pubmed: 31890830
doi: 10.1016/j.gore.2019.100512
pii: S2352-5789(19)30101-8
pii: 100512
pmc: PMC6928279
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100512Informations de copyright
© 2019 The Authors.
Déclaration de conflit d'intérêts
We have no conflict of interest to declare.
Références
Int J Gynecol Cancer. 2003 Mar-Apr;13(2):212-5
pubmed: 12657126
Int J Gynecol Pathol. 2016 May;35(3):249-55
pubmed: 26535985
Gynecol Oncol. 2009 Oct;115(1):142-153
pubmed: 19592079
Cancer. 2009 May 15;115(10):2119-27
pubmed: 19306417
Int J Gynecol Cancer. 2016 Mar;26(3):497-504
pubmed: 26825840
Gynecol Oncol. 2013 Dec;131(3):598-603
pubmed: 24135679
Am J Clin Oncol. 2019 May;42(5):472-480
pubmed: 30973371
Gynecol Oncol. 2012 Nov;127(2):321-5
pubmed: 22850412
Int J Gynecol Pathol. 2013 Mar;32(2):181-7
pubmed: 23370657